Selective Androgen Receptor Modulators-Transformative Drugs or Heralds of the Next Drug Epidemic?

Henrik A Hahamyan; Shehzad Basaria

doi:10.1001/jama.2024.1769

Selective Androgen Receptor Modulators-Transformative Drugs or Heralds of the Next Drug Epidemic?

JAMA. 2024 Apr 23;331(16):1359-1360. doi: 10.1001/jama.2024.1769.

Authors

Henrik A Hahamyan¹, Shehzad Basaria²

Affiliations

¹ James H. Quillen College of Medicine, East Tennessee State University, Johnson City.
² Section on Men's Health, Aging and Metabolism, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

PMID: 38526456
DOI: 10.1001/jama.2024.1769

No abstract available

Plain language summary

This Viewpoint examines whether selective androgen receptor modulators have the potential to be transformative drugs or whether they herald the next drug epidemic.

MeSH terms

Androgen Antagonists* / adverse effects
Androgen Antagonists* / pharmacology
Androgen Antagonists* / therapeutic use
Androgen Receptor Antagonists / adverse effects
Androgen Receptor Antagonists / pharmacology
Androgen Receptor Antagonists / therapeutic use
Clinical Trials as Topic
Drug Approval
Humans
Male
Musculoskeletal System / drug effects
Nonsteroidal Anti-Androgens / adverse effects
Nonsteroidal Anti-Androgens / pharmacology
Nonsteroidal Anti-Androgens / therapeutic use
Prostate / drug effects
Receptors, Androgen / drug effects
Receptors, Androgen / physiology
Substance-Related Disorders* / etiology
Testosterone* / pharmacology
Testosterone* / physiology
Testosterone* / therapeutic use
United States

Substances

Androgen Antagonists
Androgen Receptor Antagonists
Receptors, Androgen
Nonsteroidal Anti-Androgens
Testosterone